InvestorsHub Logo
Followers 75
Posts 4687
Boards Moderated 0
Alias Born 09/06/2003

Re: jessellivermore post# 115645

Friday, 10/06/2017 7:48:55 PM

Friday, October 06, 2017 7:48:55 PM

Post# of 426436

There is ample information, direct and indirect, that EPA does and will lower CVD risk...JELIS is something you need a couple of weeks worth of study and reflections on...Maybe you should familiarize yourself with some of the population studies and read Dr. Bernard Sears and learn about eicosanoids .



I agree that it will probably lower CVD (I.e. HR<1). The question is whether it is enough to be stat sig, clinically meaningful and without offsetting SAE.

As for Jelis, you mean that trial where the treatment arm had more deaths than the placebo arm? (Did I get that right wink.

This gap in knowledge is clear when you make comments suggesting there likely will be enough adverse events to counter any meager benefit the drug will show...This tells me and everybody on the board that does know a lot the subject, that you are just spouting wind..



Well... bleeds, certainly. But I know there is something nagging at me. Something we just discussed. Oh yeah, the excess deaths? (Do I know for sure they will show up again in the Vascepa trial? Nope, but to dismiss the risk is naive.)

More seriously, name any 'natural' substance taken at massively supraphysiologic doses that has some kind of clinical efficacy and hasn't shown meaningful AE in a large randomized trial. Not even oxygen and water are immune. The only such substances taken at such huge doses, but without AE, are those that are effectively inert. And EPA is definitely not inert at supraphysiologic doses.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News